BioMedTech Horizons

Expressions of Interest (EOIs) are now closed for the Australian Government’s $5 million BioMedTech Horizons program, an initiative to support innovative collaborative health technologies that address key health challenges.

MTPConnect called for ideas set to customise and revolutionise healthcare, stimulate inter-disciplinary collaboration between research, industry and technology sectors, and foster strong entrepreneurship potential.

Investments from the program will be focused on supporting cutting-edge ideas in precision medicine and 3D anatomical printing towards proof-of-concept and commercialisation. Innovative technologies in these areas can play a key role in significantly transforming the national healthcare system and promote Australia's international ranking as a leader in biotechnology and medical technology.

Important Dates:

  • Expressions of interest open: 1 November 2017
  • Closing date for EOI: 10 December 2017
  • Closing date for stage 2 applications: 15 January 2018
  • Announcement of successful applications: expected late February 2018

Thank you to all those who submitted their interest in the BioMedTech Horizons program, we received an overwhelming response. Only proposals moving to the next stage (Stage 2) will be notified via email on the 27th of December (Wednesday), along with the Application form and Project Code. All proposals will be on kept on record and will be offered feedback based on the panel's comments in the new year in order to strengthen future applications.

Please direct questions to MTPConnect's Project Manager, Divya Kalla on 0424 502 624 and

BioMedTech Horizons FAQ's

Q: Are there any future rounds for the BioMedTech Horizons Program?

A: BioMedTech Horizons program is a one-off grant. This program is part of the recently announced (October 2017) $35 million disbursed from the Medical Research Future Fund (MRFF). The scope and programs of the remaining $30 million will be announced in 2018.

Q: Can non-Australian industry partners be involved in the project?

A: The BioMedTech Horizons program’s mandate is to assist Australian research organisations and SMEs, the program has no restrictions on foreign owned businesses applying for projects (with Australian entities as primary applicant) where this brings benefit to Australia through collaboration and commercialisation with Australian research organisations. However, any foreign owned business needs to agree to a clause that they will deploy their IP utilisation/commercialisation within Australia (as well as globally, should they intend).

Q: Can interested groups submit more than one EOI?

A: Yes, multiple EOIs from an applicant will be accepted with unrelated research ideas or outcomes.

Q: Are companies listed on ASX eligible to apply?

A: Yes, the program is open to ASX listed entities in the MTP sector.

Q: Will MTPConnect or the Australian Government claim a stake in the Intellectual Property of the project?

A: MTPConnect or the Australian Government will not take any IP generated in this program. Public case studies delivered to MTPConnect and the Government will need to be shared, and we request a license to reproduce and use these.

Q: What is the least amount of funding available for a project?

A: Approximately $3 million is reserved for supporting ideas in precision medicine and $2 million for ideas in the 3D anatomical printing area. We expect to fund projects of approximately $1 million capacity each.

Q: Is BioMedTech Horizons a matched-funding program?

A: No, the BioMedTech Horizons program does not mandate matched-funding, but any cash or in-kind contributions from the applicant will be viewed favourably.